Stakeholders’ views sought to revise essential drugs list

Maitri Porecha New Delhi | Updated on February 13, 2019 Published on February 13, 2019

Currently, prices of at least 870 drugs have been fixed according to the National List of Essential Medicines 2015   -  luchschen

The Union Health Ministry has taken up the task of revising the National List of Essential Medicines (NLEM) and has asked for stakeholders’ participation in the process.

According to a circular issued by the Indian Council of Medical Research (ICMR), “The mandate includes - medicines, medical devices, medical disposables and consumables, hygiene and other healthcare products.”

“A meeting will be held on February 22 under the chairmanship of Balram Bhargava, Secretary, Department of Health Research, for the same,” a senior official confirmed.

The list is drawn out by the Ministry on basis of Essential List of Medicines released by World Health Organization every few years.

“Currently, NLEM includes only 20 per cent of drugs of all those that are in the market, which then go on to come under price control,” said another senior official.

Medical devices

Experts, however find regulation of medical devices through NLEM problematic. “We are still unsure if MoHFW will regulate medical devices using scientific evidence based on Health Technology Assessment in India (HTAI), a body that was set up precisely for this purpose,” said health economist Denny John.

Need to assess evidence

John said that imposing just price control in medical devices without assessing the scientific evidence may lead to over prescribing of such devices like cardiac stents or devices for knee replacement. “I don't understand why NLEM is extending it's mandate and going into devices when HTAI, a body formed in 2017 already exists,” questioned John.

Giving a recent example of price regulation for stents, John said if we need judiciary to intervene to cut down prices of cardiac stents even 60 years after Independence, then there is a serious problem in the way the systems work in our country. “In countries such as the UK, a body called NICE engages in regulating prices at which the private purchasers will buy devices from suppliers, a cost that the National Health System (NHS) then reimburses. The regulation is based on transparency and evidence,” explained John.

Published on February 13, 2019

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.